After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor. In the phase 2 study, the U.K. biopharma’s cannabidiol (CBD) and tetrahydrocannabinol (THC) candidate, both of which are active ingredients derived from cannabis, showed […]

by

Tweet It’s been an eventful week for our little green buddy: as the industry freaks out over Sessions’s confirmation, state lawmakers scramble to protect cannabis businesses in Washington, and some important clinical trials for THC and CBD-based therapies to treat brain cancer and PTSD in veterans are currently underway. Sessions Has Been Confirmed It happened: […]

by

Tweet It’s been an eventful week for our little green buddy: as the industry freaks out over Sessions’s confirmation, state lawmakers scramble to protect cannabis businesses in Washington, and some important clinical trials for THC and CBD-based therapies to treat brain cancer and PTSD in veterans are currently underway. Sessions Has Been Confirmed It happened: […]

by

Cassie Helland of Mason City jokes with her son Caleb, 12, Thursday at their home in Mason City. Caleb gets a form of medical marijuana to help treat his epilepsy through a clinical trial at the University of Iowa, but other Iowans don’t have a reliable source. … read more at: http://globegazette.com/news/opinion/editorial/sioux-city-journal-editorial-don-t-abandon-medical-marijuana-program/article_c2d2d486-ca9f-5ae8-8078-f30b41694bdb.html

by

Products containing cannabidiol are now classed as medicines in the UK The ingredient doesn’t cause a ‘high’ but aids physiological function It comes after the UK regulatory body conducted a review into the extract It means manufacturers now have to ensure products pass safety checks By Stephen Matthews For Mailonline Published: 07:54 EST, 12 October […]

by

Why Cannabis May Be the Biggest Opportunity of Our Lifetime Friday, February 10, 2017, 8:25 am – 8:55 am EST Join John O’Malley as he shares his insights as to why cannabis may be the biggest opportunity of our lifetime. He will Touch on Prohibition and War On Drugs, Colorado case study, California market and potential […]

by

DEVON, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the underwriters of its previously announced public offering of 2.8 million shares of its common stock have exercised in full their option to purchase an additional […]

by

After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor. In the phase 2 study, the U.K. biopharma’s cannabidiol (CBD) and tetrahydrocannabinol (THC) candidate, both of which are active ingredients derived from cannabis, showed […]

by

Many parents come to my office seeking help for their children suffering with autism.   The three main symptoms that are challenging for these families are communication difficulties, repetitive behaviors, and social challenges, including tantrums and self-injurious behavior.  Although the FDA has approved two medications, both antipsychotics, for treating the irritability associated with autism, they have […]

by

DEVON, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the underwriters of its previously announced public offering of 2.8 million shares of its common stock have exercised in full their option to purchase an additional […]

by

LONDON, Feb. 08, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February […]

by

DES MOINES — Caleb Helland, when he was 10 years old, was having roughly 10 atonic, or “head-drop,” seizures as a result of his intractable epilepsy. After two weeks of cannabis oil treatments, the Mason City boy’s atonic seizures stopped completely and never returned, his mother said. That was roughly a year-and-a-half ago. “He’s way […]

by